The archipelago gene (ago) encodes the F-box specificity subunit of an SCF(skp-cullin-f box) ubiquitin ligase that inhibits cell proliferation in Drosophila melanogaster and suppresses tumorigenesis in mammals. ago limits mitotic activity by targeting cell cycle and cell growth proteins for ubiquitin-dependent degradation, but the diverse developmental roles of other F-box proteins suggests that it is likely to have additional protein targets. Here we show that ago is required for the post-mitotic shaping of the Drosophila embryonic tracheal system, and that it acts in this tissue by targeting the Trachealess (Trh) protein, a conserved bHLH-PAS transcription factor. ago restricts Trh levels in vivo and antagonizes transcription of the breathless FGF receptor, a known target of Trh in the tracheal system. At a molecular level, the Ago protein binds Trh and is required for proteasome-dependent elimination of Trh in response to expression of the Dysfusion protein. ago mutations that elevate Trh levels in vivo are defective in binding forms of Trh found in Dysfusion-positive cells. These data identify a novel function for the ago ubiquitin-ligase in tracheal morphogenesis via Trh and its target breathless, and suggest that ago has distinct functions in mitotic and post-mitotic cells that influence its role in development and disease.
Introduction
The morphogenesis of branched networks of cells with a single, fused lumen plays an important role in the development of many metazoan organs, including the vertebrate lungs, vasculature, kidneys, and mammary glands. The cellular architecture of these mammalian organs is quite similar to tubular structures in simpler metazoans, suggesting that the molecular and cellular mechanisms underlying the process of branching morphogenesis are conserved. In the fruit fly Drosophila melanogaster, tubular morphogenesis underlies formation of the tracheal system, a network of interconnected tubes that duct air throughout the developing organism. The complete embryonic tracheal network is composed of approximately 1600 polarized epithelial cells that originate in early embryogenesis as 20 ectodermal placodes distributed along either side of the embryo . Each tracheal placode contains approximately 20 cells, which undergo two rounds of cell division, exit the cell cycle, and complete the subsequent stages of invagination and tracheogenesis without further cell division or cell death. Following invagination, primary branches bud from the tracheal sac and form a continuous lumen within each placode (Lubarsky and Krasnow, 2003) . The pattern of placode branching is segmentally repeated and under fixed genetic control . Budded branches extend toward their target tissues by a process of cell migration and cell extension, and subsequent fusion between adjacent tracheal metameres at later stages of embryogenesis produces a continuous, open tubular system.
Forward genetic screens for mutations that disrupt tracheal development have revealed a central role for fibroblast growth factor (FGF) signaling in promoting the post-mitotic cell migration and extension of the embryonic tracheal arbor (reviewed in Metzger and Krasnow, 1999) . The central components of the Drosophila FGF pathway are encoded by the breathless (btl) (Klambt et al., 1992) and branchless (bnl) (Sutherland et al., 1996) genes, which encode an FGF-like receptor and an FGF-like secreted ligand respectively. The role of this receptor/ligand pair in controlling tracheal outgrowth is based upon a simple model in which the restricted expression of bnl in cells outside the tracheal placode represents a directional cue for the migration of btl-expressing cells within the tracheal placode. Initial induction of btl transcription within tracheal cells depends upon the trachealess (trh) gene, which encodes a basic helix-loop-helix Per/Arnt/Sim (bHLH-PAS) domain transcription factor (Isaac and Andrew, 1996; Kuo et al., 1996; Ohshiro and Saigo, 1997; Wilk et al., 1996) most closely homologous to the mammalian NPAS1 and NPAS3 proteins (Brunskill et al., 1999; Zhou et al., 1997) . Mutation of any one of these core components -btl, bnl, or trh -produces a failure of tracheal branching. Phenotypic analysis of these and other tracheogenesis genes has shown that Btl/FGF signaling is used to promote successive rounds of primary and secondary tracheal branching during embryonic Drosophila development (reviewed in Ghabrial et al., 2003) . A similar role has been proposed for the FGF pathway in controlling the branching morphogenesis of tubes in the mammalian lung (Min et al., 1998) .
In addition to a positive role in tracheal outgrowth, experimental evidence indicates that inappropriately timed Btl/FGF signaling can also impair tracheal development. First, in the course of normal development btl expression is not constant in tracheal cells, but oscillates: initially btl mRNA rises in all placode cells at stages 10-12 preceding primary branch formation, subsequently falls during late stage 12/early stage 13, and is re-initiated in a restricted set of cells that define sites of secondary branching at late stage 13/early stage14. Unlike early btl expression, this second wave is dependent upon a bnl-dependent feedback loop (Ohshiro et al., 2002; Ohshiro and Saigo, 1997) . Second, ectopic activation of Btl, either by mutational inactivation of the btl inhibitor abnormal wing disc (awd) (Dammai et al., 2003) , or by constitutive expression of bnl (Sutherland et al., 1996) or btl (this study and Lee et al., 1996) , interferes with directed cell migration in the trachea. Similarly, expression of activated Ras or btl perturbs the ability of tracheal cells to form proper branching patterns in larval development (Cabernard and Affolter, 2005) . These observations have led to the hypothesis that spatial and quantitative restriction of Btl activity is necessary to permit normal patterns of tracheal cell migration and fusion . While many genes that modulate Btl/FGF signaling have been identified, it is likely that other as yet unrecognized mechanisms are required to restrict Btl/ FGF signaling to specific times and places in the developing organism.
Here we identify archipelago (ago), a gene known primarily for its role in cell proliferation control, as a component of the genetic circuitry that patterns the post-mitotic development of the embryonic tracheal system. ago encodes an F-box/WDrepeat protein that recruits target proteins to an SCF-type E3 Ub-ligase for subsequent poly-ubiquitination and proteolytic destruction. ago limits the division and growth of Drosophila eye epithelial cells by targeting the G1/S regulator Cyclin E and dMyc, the fruit fly ortholog of the human c-Myc protooncogene, for proteasome-mediated degradation (Moberg et al., 2001 (Moberg et al., , 2004 . A highly conserved mammalian ago ortholog (variously termed Fbw7, Fbxw7, hAgo, hCDC4, or hSel-10) also targets Cyclin E and c-Myc and is a mutational target in a rapidly expanding array of human cancers (Balakrishnan et al., 2007; Bredel et al., 2005; Calhoun et al., 2003; Hagedorn et al., 2007; Malyukova et al., 2007; Mao et al., 2004; Maser et al., 2007; Minella et al., 2007; O'Neil et al., 2007; Rajagopalan et al., 2004; Thompson et al., 2007) . Our current data indicate that ago is required for tracheal morphogenesis via a previously unrecognized target, the Trachealess (Trh) transcription factor. We find that ago mutant embryos contain excess Trh protein and ectopically express the btl gene, a known Trh target. Alleles of ago exhibit strong genetic interactions with trh and other known tracheogenesis genes, and the Ago protein is able to bind the Trh protein and regulate its proteasomal turnover via a mechanism that involves a third factor, the bHLH-PAS protein Dysfusion (Dys; Jiang and Crews, 2003) . Collectively, these data reveal a previously unappreciated developmental function for the ago tumor suppressor in the embryonic tracheal system, and identify the Trh transcription factor as a target of Ago in this process.
Materials and methods

Stocks, genetics, and statistics
The ago alleles ago 1 and ago 3 have been previously described (Moberg et al., 2001) . Unless indicated, analysis was performed on ago 1 /ago 3 transheterozygotes. Full-length ago and agoΔF, a version of ago lacking the core Fbox domain (Moberg et al., 2004) , were cloned as PCR products into the EcoRI site of the pUAST vector (Brand and Perrimon, 1993) , Df(3L)Exel9000 and esg-lacZ (all from Bloomington Drosophila Stock Center), 1-eve-1 (Perrimon et al., 1991) , btl-Gal4 (Shiga et al., 1996) , UAS-trh (Jin et al., 2001) 
Embryo immunohistochemistry and antibodies
Embryos were staged and fixed in 37% formaldehyde-saturated heptane, devitellinized in methanol and stored in ethanol at 4°C. These samples were rehydrated and washed in PBS with 0.05% Triton-X 100 (PBSTx), blocked in 5% milk powder/5% NGS in PBSTx, and incubated with the following primary antibodies: mouse anti-Tango (1:5, Developmental Studies Hybridoma Bank; DSHB), rat anti-Trh (1:200) a gift of D. Andrew (Henderson et al., 1999) , mouse mAb2A12 (1:5; DSHB), rabbit anti-β-Gal (1:300; Cappel), guinea pig anti-full length Ago (1:2500; Pocono Rabbit Farm & Laboratory), rat anti-Dys (1:200) and rabbit anti-Dys (1:800) both a gift of S. Crews (Jiang and Crews, 2003 
RNA analysis
RNA in situ hybridization was performed as described (Tautz, 2000) . Briefly, embryos were fixed in 1.5% formaldehyde (in 0.1 M HEPES, pH 6.9, 2 mM MgSO 4 , 1 mM EGTA)-saturated heptane, devitellinized, and stored in methanol at −20°C. Embryos were washed in PBS with 0.1% Tween 20, treated with 15 μg/ml Proteinase K for 2 min, and post-fixed with 4% paraformaldehyde. Riboprobe hybridization and subsequent immunohistochemistry were performed as described (Tautz, 2000) . Sense and anti-sense digoxigenin (DIG)-labeled riboprobes were synthesized from a 1 kb PCR fragment amplified from btl cDNA and visualized by the anti-DIG-AP antibody (1:2000; Roche).
Plasmids and molecular biology pMT-HA-ago expression plasmids have been described previously (Moberg et al., 2004) . pMT-Flag-trh was generated by cloning the full-length trh ORF (Open Biosystems) into the pMT vector as an N-terminally Flag-tagged PCR product. The pACT-HA-dys plasmid (gift of S. Crews) contains an N-terminally tagged version of the dys ORF under the control of a constitutively active fragment of the actin promoter. Transfected S2 cells were induced by the addition of 0.5 mM CuSO 4 for 6 h prior lysis in buffer containing 0.5M KCl, 0.1% NP-40, 35% glycerol, 10 mM HEPES pH 7.0, 5 mM MgCl 2 , 0.5 mM EDTA pH 8.0, 25 mM NaF, 1 mM Na 2 VO 4 , 1 mM DTT supplemented with protease inhibitors (Complete™ Protease Inhibitor Cocktail; Roche). Where indicated, 50 μM MG132 (Calbiochem) was added 6 h prior to harvesting cells. Lysates were analyzed directly by immunoblot (IB), or diluted in immunoprecipitation (IP) buffer and subject to IP/IB analysis as described previously (Moberg et al., 2004) .
Results
ago has role in embryonic tracheal development
Analysis of the growth restrictive role of ago in proliferating larval imaginal disc cells has provided an excellent model to understand the tumor suppressive properties of ago mammalian orthologs. However, the Ago protein is widely expressed in the early embryo ( Fig. 1 ) and mutations that disrupt it lead to embryonic death (Moberg et al., 2001) . Intercrossing the ago 1 or ago 3 alleles (respectively encoding a C-terminal truncation in the WD-repeat/substrate-binding domain and a G1131E missense mutation in the 4th WD repeat; Moberg et al., 2001) produces trans-heterozygous mutant embryos that develop through all embryonic stages but fail to hatch as L1 larvae (data not shown), suggesting lethality occurs during late embryogenesis. The severity of this and other phenotypes (see below) in homozygous or heteroallelic mutant animals is indistinguishable from those carrying either allele in trans to a chromosomal deficiency that removes the ago locus (Table 1 ; Df(3L) Exel9000), indicating that ago 1 and ago 3 are either null or strong loss-of-function alleles. Considered together, these observations indicate that ago may have as yet unappreciated roles in early development.
The earliest morphological defects in ago zygotic mutant embryos are observed in the developing trachea visualized with the anti-lumen antibody mAb2A12 (Figs. 2C-F). This analysis reveals two major defects in tracheal branching patterns of ago embryos. The first of these is interruptions, or 'breaks', in the continuity of the tracheal lumen (Figs. 2C-E). The breaks occur throughout the tracheal system and are prominent in the dorsal trunk (DT; Figs. 2C, D, arrowheads), the lateral truck (LT; Fig.  2C , arrows), and between dorsal branches of opposing tracheal placodes (DB; Fig. 2E , arrow). What appears to be a misrouting phenotype is also observed in the dorsal branches ( Fig. 2E , arrowhead) and ganglionic branches (data not shown). Approximately 70% of all ago mutant embryos show combinations of these break or misrouting effects. The second prominent tracheal phenotype (occurring in ∼ 25% of all ago mutant embryos) is excess lumen convolution throughout the primary and secondary branches (Fig. 2F ). This combined spectrum of breaks, apparent misrouting, and convolution indicates that ago is required for normal development of the tracheal system. Moreover, the absence of any accompanying defects in the major morphogenetic events of embryogenesis (NTM and KHM, unpublished) suggests that these phenotypes reflect a requirement for ago in the trachea, rather than as a secondary effect of a more general developmental role outside this tissue. The DT break phenotype occurs in almost half of all ago mutant embryos (46%, n = 85) with an average of 1.2 ± 0.09 breaks among those that show the phenotype (n = 39). On a per fusion event basis, this corresponds to a greater than 15-fold increase in the rate of defective interplacode fusion events in ago mutants compared to control embryos (Supplemental Fig.  1 ). Due to the prevalence of this phenotype, DT morphogenesis was selected as a system in which to characterize the role of ago in the developing tracheal system. To investigate the cellular architecture of DT breaks in ago mutant embryos, the 1-eve-1 enhancer trap line, which carries a lacZ insertion in the trh gene and expresses β-galactosidase (β-gal) in every tracheal cell (Perrimon et al., 1991; Wilk et al., 1996) , was placed in the wild type and ago mutant backgrounds (Figs. 2B, D) . Anti-β-gal staining of these embryos reveals that lumenal gaps detected with the mAb2A12 antibody reflect physical gaps between cells of adjacent tracheal placodes (Fig. 2D, arrowhead) . Interplacode fusion along the DT is normally dependent upon specialized 'fusion cells', which are specified 2 per placode by a Notchdependent process (Ikeya and Hayashi, 1999) . At the appropriate stage, one migrates anteriorly and the other posteriorly to meet with fusion cells coming from adjacent placodes. Thus, the gaps between adjacent DT placodes in ago mutant embryos suggest either that ago is necessary for proper fusion cell specification, or that ago mutations impair fusion cell migration and/or fusion. To test these hypotheses, DT fusion cells were visualized in wild type and ago mutant stage 15 embryos (Figs. 2G, H) using the fusion cell-specific enhancer trap escargot (esg)-lacZ . Analysis of wild type embryos in which the process of DT fusion is complete shows esg-lacZ expression (purple nuclei; Fig. 2G ) in a pair of adjacent fusion cell nuclei. In ago mutant embryos, pairs of esg-lacZ positive fusion cells flank regions of DT breaks (Fig.  2H , arrows mark fusion cell nuclei, arrowhead marks gap in DT). Analysis of a second fusion cell marker, the Dysfusion protein (Jiang and Crews, 2003) , gives similar results (data not shown). Thus ago DT breaks are not associated with altered fusion cell numbers but rather a failure of ago mutant DT fusion cells to fuse with adjacent placodes. This differs significantly from tracheal phenotypes elicited by btlGal4-driven overexpression the putative Ago target Notch (Fryer et al., 2004; Gupta-Rossi et al., 2001; Oberg et al., 2001; Tsunematsu et al., 2004; Wu et al., 2001) , which results in a complete loss of fusion cells (Ikeya and Hayashi, 1999) . The lack of an effect on fusion cell number also contrasts with ago proliferative phenotypes in imaginal discs (Moberg et al., 2001 (Moberg et al., , 2004 . To further confirm this, we measured total cell number in wild type and ago mutant DTs using an anti-Tango antiserum (Sonnenfeld et al., 1997) . This analysis shows that these genotypes have approximately equal numbers of nuclei per DT segment (wt = 16.7 ± 0.4, n = 6; ago = 17.0 ± 0.7, n = 9). Thus, the primary effect of ago loss in the DT is not on cell number, but rather on the ability of cells to follow the normal developmental program of cell migration and fusion.
Because Ago protein is expressed uniformly in tracheal and non-tracheal cells (Supplemental Fig. 1) , the requirement for ago in the DT could be indicative of a cell-autonomous role for ago in tracheal cells or it might reflect a non-cell autonomous role for ago outside the developing placode in, for example, the mesodermal 'bridge cells' necessary for DT fusion (Wolf and Schuh, 2000) . To determine the site of ago action, a wild type UAS-ago transgene and a dominant-negative UAS-agoΔF transgene were expressed specifically in the developing tracheal system using the btl-Gal4 driver (Shiga et al., 1996) . btl-Gal4-driven expression of wild type ago in an ago 1 /ago 3 mutant background significantly reduces the frequency of DT breaks (Fig. 3E , compare yellow and blue bars) and the other observed tracheal phenotypes in ago mutant embryos (data not shown). Moreover, btl-Gal4-driven expres- sion of the agoΔF dominant-negative transgene in otherwise wild type tracheal cells is sufficient to produce DT breaks at similar penetrance as zygotic deficiency for ago (Table 2 and Figs. 3A, D). The agoΔF allele carries an internal deletion of the core F-box domain (Moberg et al., 2004) , and is defective in ubiquitin-dependent protein degradation. While these data do not rule out a secondary role for ago in non-tracheal cells, they do argue that ago plays a required role in a protein degradation pathway that is active in embryonic tracheal cells.
ago acts upstream of trachealess and breathless
Because loss of ago leads to excess activity of proteins normally regulated by Ago-dependent degradation (Moberg et al., 2001 (Moberg et al., , 2004 , known Ago target proteins were tested for their ability to reproduce ago mutant tracheal phenotypes when expressed in the btl-Gal4 domain. Expression of cycE and dMyc, two targets of Ago in imaginal disc cells, does not reproduce the ago mutant tracheal phenotype ( Table 2 ), suggesting that ago controls tracheal morphogenesis via a novel target. Significantly, btl-Gal4-driven expression of either trh or its downstream target btl produces DT breaks of similar penetrance and expressivity as ago mutations (Figs. 3B-D) , and also leads to lumen convolution (data not shown). Moreover, loss-of-function alleles of trh (trh 10512 ; Isaac and Andrew, 1996) or btl (btl dev1 ; Kennison and Tamkun, 1988) are each able to dominantly suppress ago tracheal phenotypes (Fig.  3E , green and red bars, respectively). The sensitivity of ago phenotypes to the genetic dosage of trh and btl suggests that ago may inhibit Trh in the developing trachea. To test the effect ago mutations on Trh protein levels, wild type and ago mutant embryos were stained with a Trh-specific antiserum (Fig. 4) . Compared to control embryos, ago mutant embryos contain significantly higher levels of Trh in all tracheal cells (Figs. 4A, B) . This effect is also evident in immunoblot blot analysis of Trh levels in ago and control embryos (Fig. 4C) . Trh protein is normally detected in the nuclei of all tracheal cells, but is specifically eliminated from fusion cells, including those of the dorsal trunk, by a mechanism that requires fusion-cellspecific expression of the Dysfusion (Dys) bHLH-PAS domain transcription factor (Jiang and Crews, 2003) . In addition to limiting the steady-state levels of Trh in all tracheal cells, ago is also required for the Dys-stimulated elimination of Trh that occurs specifically in fusion cells (Figs. 4D, E) . Expression of Dys occurs normally in ago embryos (see middle panel, Fig.  4E ), but in these same cells Trh levels do not decline, and DT fusion cells with high levels of both Dys and Trh are readily observed (Fig. 4E, arrows) . Thus, the antagonistic genetic interaction between ago and trh in the tracheal system appears to have its basis in a requirement for ago in limiting the steadystate levels of Trh in all tracheal cells, and in the specific elimination of Trh from fusion cells.
The effect of ago alleles on Trh levels, and the genetic interaction between ago and the Trh target gene btl, indicates that ectopic Trh-driven transcription of btl may contribute to the ago phenotype. The developmental regulation of the btl promoter is complex and involves inputs from a number of factors other than Trh, including the transcriptional activators pointed (Klambt, 1993; Ohshiro et al., 2002) and ventral veinless (Anderson et al., 1996) , and the transcriptional repressors anterior open (Ohshiro et al., 2002) and spalt (Kuhnlein and Schuh, 1996) . To test whether the failure to down-regulate Trh in ago mutant cells is sufficient to cause misexpression of btl, RNA in situ hybridization analysis was performed using a btl-specific anti-sense RNA probe. In stage 15 control embryos, levels of btl mRNA expression in the DT do not rise above the background signal obtained with btl antisense (Fig. 5A ) or sense (data not shown) probes. In contrast, pairs of btl-positive cells are evident along the DT of all ago mutant embryos (Fig. 5B, see arrows) . The location and pattern of this ectopic btl expression suggest that these paired cells correspond to fusion cells, and that failure to eliminate Trh in these cells leads to ectopic btl transcription. The lack of a similar effect in the remaining ago mutant tracheal cells suggests that excess Trh must collaborate with fusion-cellspecific factors in order to drive ectopic btl transcription.
In view of the requirement for btl in the ago phenotype (see Table 3 and Fig. 3B ) and the finding that excess Btl activity disrupts DT architecture (see Fig. 3B and Dammai et al., 2003; Lee et al., 1996; Ohshiro et al., 2002) , the effect of ago on btl suggests that Trh-driven transcriptional deregulation of btl is an important element of ago DT phenotype. However, while the molecular effect of ago inactivation on Trh and btl is fully penetrant, the resultant morphological defects in tracheal structure are not. This might be expected if the elevated levels of Trh and btl reach a threshold that is sufficient to perturb tracheal development in a portion of embryos, but that other pathways acting redundantly to ago are able to enforce the developmental down-regulation of the Btl pathway. If so, then ago mutations might be predicted to sensitize the tracheal system to other mutations that increase Btl activity by nontranscriptional mechanisms. To test this, a loss-of-function allele of the abnormal wing discs gene (awd j2A4 ; Spradling et al., 1999) , which encodes a factor that promotes the endocytic down-regulation of the Btl receptor in embryonic tracheal cells (Dammai et al., 2003) , was assayed for its ability to enhance the ago tracheal phenotype (Figs. 5C, D) . Reducing awd gene dosage by half in ago mutant animals strongly enhances both the penetrance (from 46% of embryos to greater than 80% of embryos; see Fig. 5D , Table 4 , and Supplemental Fig. 1 ) of the DT break phenotype and its expressivity among affected embryos (from 1.2 ± 0.09 breaks/embryo, n = 39 to 6.1 ± 0.95 breaks/embryo, n = 41). These ago/ago,awd/+ embryos also show a much more severe disruption of the entire tracheal system than do ago mutants alone (compare Figs. 5C to 2C). Moreover, a significant fraction of ago/+,awd/+ trans-heterozygous embryos show DT breaks. In view of the data indicating that ago and awd are both upstream of btl via transcriptional and endocytic mechanisms, respectively, these strong synthetic effects suggest that ago and awd mutations collaborate to deregulate Btl in the developing tracheal system.
Ago binds Trh and restricts Trh levels in cells
The ability of ago mutations to elevate Trh levels in vivo and to uncouple Trh levels from the rise in Dys indicates that Ago acts downstream of Dys as part of the mechanism that eliminates Trh protein in fusion cells. To examine interactions between Ago and Trh more closely, epitope tagged versions of these proteins were co-expressed in S2 cells (Figs. 6A, B) . Analysis shows that while Trh accumulates to high levels when expressed in S2 cells, co-expression of Ago results in a subtle but reproducible reduction (∼ 20% by density quantitation; Photoshop) in Trh levels (Fig. 6A, top panel, lanes 1-2) . This effect appears to parallel the negative effect ago has on Trh levels in non-fusion cells that do not normally express Dys (see Fig. 4B ). However, when Ago and Trh are co-expressed with Dys, the in vivo trigger of Trh down-regulation, Trh levels drop dramatically (Fig. 6A, top panel, lane 3 ) in much the same way Trh levels drop in response to Dys expression in vivo (see Fig.  4D and in Jiang and Crews, 2003) . The parallel decline in the level of Ago is consistent with findings that other F-box proteins are destabilized by reductions in the level of their substrates and mimics the relationship between dMyc and Ago stability in S2 cells (Moberg et al., 2004) . Examination of the effect of Dys on Trh reveals that expression of dys is sufficient to decrease Trh levels in the absence of exogenous Ago (Fig. 6B, lane 3) . However, as is observed in embryonic tracheal cells (Fig. 4E) , this effect of Dys in S2 cells still requires endogenous Ago since RNAi-knockdown of ago is sufficient to block it (Fig. 6B, lane 4) . Addition of the proteasome inhibitor MG132 also blocks the Ago/Dysstimulated decline in Trh levels in S2 cells (Fig. 6B, lane 5) . In parallel to these in vitro effects, btl-Gal4-mediated expression of dominant-negative alleles of the proteasome subunits Pros26 and Prosβ2 (Belote and Fortier, 2002 ) is sufficient to phenocopy ago alleles and block down-regulation of Trh in embryonic fusion cells (Fig. 6C) . From these data, it appears that Trh is a target of a proteasomal degradation pathway in embryonic tracheal cells and in cultured S2 cells, and that in both cases the mechanism underlying this effect requires ago and can be greatly potentiated by co-expression of dys.
The genetic and functional interactions between ago and trh suggest that their encoded products may physically interact in cells. To test this hypothesis, Flag-tagged Trh and HA-tagged versions of either wild type Ago, the AgoΔF dominant negative protein, or the truncated Ago 1 protein (lacking an intact WD domain) were expressed in S2 cells and analyzed by coimmunoprecipitation (Fig. 7) . Wild type Ago, Ago 1 , and AgoΔF are all recovered in anti-Flag immunoprecipitates (Fig. 7A, lanes 2-4) and reciprocally, Flag-Trh is readily detected in anti-HA immunoprecipitates from cells expressing HA-AgoΔF (Fig. 7B) . Thus, in the absence of exogenous Dys, Trh is able to interact with all three forms of Ago in S2 cells, including the Ago 1 WD-truncation mutant that is defective in Trh regulation in vivo. Co-expression of Dys with these combinations of Ago and Trh, and simultaneously blocking proteasome function so as to stabilize the Ago-Trh complex, induces a significant change the nature of the Ago-Trh interaction (Fig. 7C) . The form of Trh protein that accumulates in MG132-treated, Dys-expressing cells remains competent to bind wild type Ago but fails to interact with the WD-truncation mutant Ago 1 (Fig. 7C , top panel, compare lanes 3 and 5). Thus, an ago mutation that deregulates Trh levels in vivo is defective in binding to the form of Trh normally targeted for proteasomedependent elimination in Dys-expressing fusion cells. Considered together, these data show that Ago and Trh can bind specifically to one another, and that this interaction is required to limit Trh levels in vivo.
Discussion
The biological properties of individual F-box proteins are to a large degree determined by their repertoire of target proteins. In the case of the Drosophila Ago F-box protein, failure to degrade these targets promotes excess proliferation of imaginal disc cells. This observation has led to the identification of Cyclin E and Myc proteins as ago targets (Moberg et al., 2001 (Moberg et al., , 2004 . However, the broad pattern of Ago expression in the embryo suggests that it might regulate distinct processes and targets in other cell types. In view of the rapidly growing body of work showing that inactivation of human ago/Fbw7 is a common event in a variety of cancers (e.g. Malyukova et al., 2007; O'Neil et al., 2007; Thompson et al., 2007) , identification of these targets may provide important insight into the biology of cancers lacking ago function.
Here we show that Drosophila Ago is required for the postmitotic morphogenesis of the embryonic tracheal system and that this requirement is due, at least in part, to the ability of Ago to bind directly to a previously unrecognized target, the Trh transcription factor, and stimulate its proteasomal degradation. This ago degradation mechanism appears to fulfill different regulatory roles in different populations of tracheal cells. In non-fusion tracheal cells, ago is required to limit overall levels of Trh, which is normally expressed at moderate levels throughout the tracheal system. In tracheal fusion cells, the ago degradation mechanism appears to be strongly potentiated by an unidentified signal generated by Dys, such that Trh is completely eliminated from Dys-expressing cells. At a genetic level, the dependence of ago tracheal phenotypes on trh gene dosage argues that that elevated Trh levels are primarily responsible for branching defects that occur in ago zygotic mutant embryos. In support of this, persistent Trh expression is also observed in ago mutant fusion cells in other tracheal branches (NTM and KHM, unpublished observation) . This novel role for Ago in tracheal development is supported by the independent finding that homozygosity for a genomic deletion containing the ago locus is associated with cell migration defects in embryonic tracheal metameres (Myat et al., 2005) . Many important developmental events are controlled by multiple mechanisms that collaborate to regulate a key step in the process. This somewhat redundant control insulates the process from defects in any single pathway, such that major defects only occur when multiple control mechanisms are blocked. The observation that the effect of ago mutations on Trh and btl levels is completely penetrant, but the resulting morphological defects are not, suggests that another pathway acts redundantly to ago to control tracheal development. The strong, dominant enhancement of the ago phenotype by a mutation in the awd gene fits very well into a model in which multiple pathways are responsible for the precisely timed down-regulation of the Breathless/FGF pathway: ago attenuates btl transcription by degrading Trh, awd lowers levels of Btl protein on the cell surface by promoting its endocytic internalization (Dammai et al., 2003) , and other pathways act independently to control expression of the FGF ligand branchless in non-tracheal cells (Merabet et al., 2005; Sutherland et al., 1996) . Thus, the incomplete penetrance of the ago phenotype is not indicative of an insignificant role for the gene in tracheal development, but rather may indicate that the tracheal system uses multiple mechanisms to redundantly control a key step in its development.
The Ago WD repeat region binds Cyclin E and dMyc, and the current work demonstrates that it also binds Trh. Broadly, the Ago-Trh interaction is quite similar to interactions with Cyclin E and dMyc: it is required for the down-regulation of substrate levels in vivo, and its disruption elevates levels of substrate that then drive downstream phenotypes. For substrates like Myc, site-specific phosphorylation generates a motif that binds to the Ago WD-region and stimulates rapid, SCFmediated protein turnover of the target protein (reviewed in Minella and Clurman, 2005) . In contrast, the data here suggest that Trh can physically interact with Ago in two distinct configurations: one that does not require an intact WD-domain and a second WD-dependent mode of binding. The observation that the Ago 1 allele can participate in the first complex but not the second and is defective in Trh regulation in vivo, suggests that like other Ago targets, WD-dependent binding is associated with rapid Trh turnover. Expression of Dys appears to shift the balance in favor of this second mode of binding. Combined with the genetic and phenotypic data implicating ago as an in vivo regulator of Trh activity, these molecular data support a model in which Ago can bind to Trh in the absence of Dys and inefficiently stimulate Trh turnover by a WD-dependent mechanism. This inefficient mechanism may be responsible for the fairly mild increase in Trh levels observed in all ago mutant dorsal trunk cells. However, in the presence of Dys, the efficiency of Trh turnover in DT fusion cells is enhanced to the degree that the entire pool of Trh is rapidly eliminated. Interestingly, the correlate of this hypothesis -that ectopic expression of dys in non-fusion cells should be sufficient to trigger down-regulation of endogenous Trh -was confirmed in a recent study (Jiang and Crews, 2006) .
The nature of the Dys-generated signal responsible for this effect is not currently known. Precedent with other Ago targets suggests that it may involve Trh phosphorylation (Fryer et al., 2004; Koepp et al., 2001; Nateri et al., 2004; Sundqvist et al., 2005; Wei et al., 2005; Welcker et al., 2003 Welcker et al., , 2004 Yada et al., 2004; Ye et al., 2004) . Recent work on the mammalian ago ortholog Fbw7 has shown that interactions with substrates can also be modulated by interaction with accessory factors (Punga et al., 2006) , or by conformational changes in the substrate driven by the isomerization of proline residues within the Ago/ Fbw7 binding motif (van Drogen et al., 2006) . Proline isomerization has been implicated in the degradation of mammalian c-Myc (Yeh et al., 2004 ), but such mechanisms are not currently known to play a role in the degradation of either Myc or bHLH-PAS proteins in Drosophila. An important goal of future studies will be to determine if any of these types of mechanisms are involved in Dys-induced Trh degradation in tracheal cells.
The requirement for ago in tracheal cells suggests that the consequences of ago loss vary considerably depending on the proliferative state of the cells, their location within the organism, and their developmental stage. ago mutant clones in the mitotically active larval eye disc show no evidence of excessive Trh levels or deregulated Btl/FGF signaling (NTM and KHM, unpublished) and conversely, ago zygotic mutant trachea do not display 'extra cell' defects similar to those observed in the eye. The origins of this tissue specificity are currently not clear, although it might simply reflect the differential expression patterns of Ago targets in various mitotic and post-mitotic cell populations. There is currently no evidence that the mammalian Trh homologs NPAS-1 and NPAS-3 are degraded by an Ago/Fbw7-dependent mechanism in mammalian cells. However, the finding that Fbw7 knock-out mouse embryos display defects in vascular development (Tetzlaff et al., 2004; Tsunematsu et al., 2004) seems to indicate that the Fbw7 ligase may also target proteins involved in tubular morphogenesis, and intriguingly both NPAS1 and NPAS3 have been linked either to this process (Levesque et al., 2007) or to the transcriptional control of FGFR genes (Pieper et al., 2005) . It has been suggested that the Fbw7 vascular defects arise due to Notch misregulation. However, since FGF signaling is known to control branching morphogenesis of the mammalian vasculature and lung (Min et al., 1998; Walgenbach et al., 1995) , the data presented here raise the possibility that vascular phenotypes in Fbw7 knock-out mouse embryos may also reflect the deregulation of developmental pathways that control branching morphogenesis via mammalian homologs of trh and btl.
